PLOS ONE | https://doi.org/10.1371/journal.pone.0203986 October 3, 2018
Rueda S, et al. BMJ Open 2016;6:e011453. doi:10.1136/bmjopen-2016-011453
SADC Communicable Disease Project
Component 5: Scaling-up Child and Adolescent HIV, TB and Malaria Continuum of Care and Support
DRAFT POST REGIONAL CONSENSUS AND VALIDATION MEETING Oct 2012
Editorial Review
AIDS 2019, 33:1411–1420
PLOS ONE | https://doi.org/10.1371/journal.pone.0183180 October 9, 2017
2018
Vol.5 No.2:73
DOI: 10.21767/2254-9137.100092
Health Systems and Policy Research ISSN 2254-9137
Review
Drake AL et al. Journal of the International AIDS Society 2019, 22:e25271 http://onlinelibrary.wiley.com/doi/10.1002/jia2.25271/full | https://doi.org/10.1002/jia2.25271
This handbook is a quick-reference tool that provides practical, field-level guidance to establish and maintain a GBV sub-cluster in a humanitarian emergency. It provides the foundations for coordination. More in-depth information can be pursued through resources referenced in this handbook. The GBV... AoR website (gbvaor.net) maintains a repository of tools, training materials and resources that complement this handbook. As a second edition, this handbook provides updates to practitioners on humanitarian reforms, lessons learned, promising practices and resources that have emerged since its first publication in 2010.
more
Technical Brief
Damon Barrett, Gonçalo Figueiredo Augusto, Martiani Oktavia, Jeanette Olsson, Mira Schneiders and Kate Welch provided background papers and literature reviews which informed this technical series.
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Research Article
PLOS ONE | https://doi.org/10.1371/journal.pone.0189770 January 2, 2018
BMC Public Health (2016) 16:766
DOI 10.1186/s12889-016-3455-5
Rutstein SE et al. Journal of the International AIDS Society 2017, 20:21579 http://www.jiasociety.org/index.php/jias/article/view/21579 | http://dx.doi.org/10.7448/IAS.20.1.21579
Report
A Project of the Joep Lange Institute July, 2018